Questcor Pharma (QCOR) Weakens as Einhorn Said Short
Get Alerts QCOR Hot Sheet
Join SI Premium – FREE
(Updated - July 25, 2014 12:56 PM EDT)
Questcor Pharma (NASDAQ: QCOR) seeing some weakness as David Einhorn said to be short.
NOTE: QCOR is in an merger deal with Mallinckrodt plc (NYSE: MNK).
UPDATE: In its Q2 letter, Greenlight noted it bought a media-sized stake in Mallinckrodt plc at an average price of $63.17 after the deal with Questcor was announced. Subsequently, they spoke to MNK's CEO and "ascertained that he is blowing smoke over his evaluation of the many risks facing H.P. Acthar Gel. Most notablly, he said that a bilogial test, rather than a chemical test, is the proper way to evaluate the activity of the drug. We believe this misses the point since QCOR has admitted that H.P. Acthar Gel only contains deamidiated Acthar, which is not the compound indicated on the FDA-approved label, and therefor an untested, unapproved drug." Einhorn said he has since dumped MNK.
Given that QCOR is larger than MNK, and MNK is going to lever-up to buy QCOR, they believe that MNK is setting itself up to be a "very attractive short sale candidate" if the merger is completed.
Greenlight's short on QCOR was the only significant loser in the quarter, advancing from $64.93 to $92.49.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mobix Labs (MOBX) Secures $100M Committed Equity Facility
- Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
- Redwood Trust and CPP Investments Announce $750 Million Strategic Capital Partnership
Create E-mail Alert Related Categories
Short Sales, Trader TalkRelated Entities
Greenlight Capital, David Einhorn, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!